2024-06-30错误0001627281Q2--12-310001627281clls:Calyxt会员2024-01-012024-06-300001627281clls:Tranche B warrants会员2024-01-250001627281clls:估计公允价值会员2024-06-300001627281clls:Bpifrance会员clls:授权和可退还垫款协议会员2023-04-012023-06-300001627281ifrs-full:股份溢价会员2024-01-012024-06-300001627281clls:SA免费股票会员2024-01-012024-06-300001627281ifrs-full:一年后但不迟于三年成员电芯:许可与合作协议成员2023-12-310001627281建筑物ifrs全文:租赁资产成员2023-01-012023-06-300001627281电芯:无风险利率成员2023-11-140001627281电芯:A期权成员2023-04-172023-04-170001627281电芯:股票期权1成员2023-01-012023-12-310001627281电芯:Astra Zeneca成员2023-11-140001627281ifrs-full:超过一年但不超过五年的其他长期负债2023-12-310001627281电芯:A档认购权证会员电芯:欧洲投资银行贷款会员2023-04-170001627281电芯:首位受试者I期剂量相关里程碑达成会员2024-06-300001627281ifrs-full:晚于五年的会员2023-12-310001627281ifrs完整版:非控制权益成员2024-01-012024-06-300001627281ifrs全文:租赁资产成员2023-12-310001627281电芯:B档认购权证会员2024-01-252024-01-250001627281电芯: 远期外汇汇率期权会员2023-11-140001627281电芯: 租赁设备会员stpr:NC2024-06-300001627281电芯: Calyxt公司会员2023-06-012023-06-010001627281IFRS全面:其他综合收益累计额成员2022-12-310001627281电芯: A档权证会员2023-04-172024-06-300001627281电芯: Cibus公司会员2023-12-310001627281电芯: Cellectis Sa会员ifrs完整版:归属于母公司股东的权益成员2023-01-012023-06-300001627281电芯:阿斯利康会员最高限度会员电芯:联合合作与研究协议会员2023-11-012023-11-010001627281电芯:租赁场地会员stpr:NC2024-06-300001627281电芯:研究税收抵充融资会员电芯:其他非流动财务负债会员2023-12-310001627281ifrs-full:在建工程成员2024-06-300001627281电芯:联合合作与研究协议成员2024-01-012024-06-300001627281电芯:SA免费股份成员2023-12-310001627281电芯:股票期权1成员2022-01-012022-12-310001627281ifrs全文:土地和建筑成员2024-01-012024-06-300001627281电芯:欧洲投资银行贷款成员2023-04-170001627281电芯:非雇员认股权证成员2024-01-012024-06-300001627281IFRS全面:保留盈余成员2024-06-3000016272812024-03-050001627281clls: A类可转换优先股会员2023-11-140001627281IFRS全面:其他综合收益累计额成员2023-01-012023-06-3000016272812023-06-012023-06-300001627281clls: 研究税收信贷融资会员clls: 其他非流动财务负债会员2023-08-310001627281ifrs-full:股份溢价会员2023-12-310001627281clls: 资本进化2024会员2024-05-2800016272812022-11-232022-11-230001627281clls: Cellectis生物制品公司会员clls: Cellectis公司会员2024-01-012024-06-300001627281电芯:阿斯利康成员2023-11-010001627281纽约电芯:其他非流动财务负债成员2024-06-300001627281电芯:股票期权1成员2023-12-310001627281最高限度会员电芯:联合合作和研究协议成员2023-11-010001627281电芯:2024资本发展成员2024-05-120001627281国家: 法国2024-04-012024-06-3000016272812024-06-300001627281ifrs完整版:非控制权益成员2024-06-300001627281国家: 法国2024-01-012024-06-300001627281clls:许可协议会员IFRS-全面收录:三年以上但不超过五年的成员2024-06-300001627281ifrs-full:在建工程成员2023-06-300001627281clls:初始投资协议会员2024-01-012024-06-300001627281clls:授予和可退还预付款协议会员2023-03-082023-03-080001627281clls:Primera Therapeutics Inc会员2023-05-172023-05-170001627281clls:携带金额和价值会员2024-06-3000016272812023-11-140001627281clls:应计及未支付利息应计会员clls:Cytovia 协议会员2024-06-300001627281clls:期权 1 会员2023-01-012023-06-300001627281IFRS全面:其他综合收益累计额成员2023-12-310001627281clls:研究税收抵充融资会员clls:其他非流动财务负债会员2024-06-300001627281clls:许可和合作协议会员2023-12-310001627281电芯:许可协议成员2024-06-300001627281电芯:研究税收抵免融资成员电芯:其他非流动财务负债成员2022-06-300001627281电芯:外国公民成员电芯:SA免费股票成员2024-01-012024-06-300001627281ifrs全文:租赁资产成员2023-01-012023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2024-06-300001627281电芯:B 配售权 成员2024-01-252024-06-300001627281电芯:临床和研发协议 成员ifrs-full:一年后但不迟于三年成员2024-06-300001627281ifrs完整版:非控制权益成员2022-12-310001627281电芯:法国居民员工 成员电芯:SA免费股票 成员2024-01-012024-06-300001627281电芯:联合合作与研究协议 成员2023-11-012023-11-010001627281电芯:后续投资协议 成员clls:资本进化2024会员2024-06-300001627281clls:Cellectis Sa会员2023-01-012023-06-300001627281clls:联合研究与合作协议会员2023-01-012023-12-310001627281clls:IT许可协议会员IFRS-全面收录:三年以上但不超过五年的成员2023-12-310001627281clls:税务诉讼准备金会员2023-12-310001627281IFRS-全面收录:三年以上但不超过五年的成员2024-06-300001627281clls:国家担保贷款会员最高限度会员2024-06-300001627281电芯:A期权会员2024-01-012024-06-300001627281电芯:法国雇员会员电芯:SA免费股票会员2024-01-012024-06-300001627281电芯:国家担保贷款会员2024-06-300001627281IFRS-全面收录:三年以上但不超过五年的成员2023-12-310001627281电芯:技术设备会员2023-12-310001627281电芯:授汇和可退还预付协议会员ifrs-full:AtFairValueMember2024-06-300001627281电芯:临床和研发协议成员2024-06-300001627281ifrs完整版:归属于母公司股东的权益成员2022-12-310001627281电芯:授予和可退还预付款协议成员2023-06-190001627281IFRS全面:保留盈余成员2022-12-310001627281IFRS全面:保留盈余成员2023-01-012023-06-300001627281电芯:汇率调整会计成员2024-01-012024-06-300001627281建筑物ifrs全文:租赁资产成员2023-06-300001627281电芯:阿斯利康成员2023-11-012023-11-010001627281ifrs-full:一年后但不迟于三年成员2023-12-310001627281ifrs-full:股份溢价会员2022-12-310001627281电芯:阿斯利康成员2024-06-300001627281电芯:联合合作和研究协议成员2024-03-042024-03-040001627281电芯:Bpifrance成员电芯:拨款和可退还预付款协议成员2023-01-012023-06-300001627281电芯:授予与可退还预付款协议成员2024-01-012024-06-300001627281电芯:绩效股单元成员电芯:卡利特斯成员2023-01-012023-06-300001627281电芯:后续投资协议成员2023-11-012023-11-010001627281电芯:非员工认股权证成员2023-01-012023-06-300001627281电芯:阿斯利康成员2024-05-030001627281电芯:第B批认股权证成员2024-01-242024-01-240001627281电芯:临床与研发协议成员2023-12-310001627281ifrs-full:不迟于一年会员2024-06-300001627281电芯:其他费用准备会员2024-06-300001627281最高限度会员电芯:股权奖励会员2023-01-012023-06-300001627281电芯:B段认股权证会员2024-01-250001627281电芯:欧洲投资银行贷款会员2022-12-280001627281电芯:股票期权 1 会员电芯:Calyxt 会员2023-01-012023-06-3000016272812024-01-012024-06-300001627281ifrs完整版:归属于母公司股东的权益成员2023-06-300001627281电芯:修正协议一名成员电芯:Cytovia协议成员ifrs-full:债务证券成员电芯:Cellectis成员2022-04-012022-04-300001627281国家:美国2023-04-012023-06-300001627281电芯:Calyxt成员2023-05-312023-05-310001627281最低限度会员电芯:股权奖励会员2024-01-012024-06-300001627281IFRS全面:其他综合收益累计额成员2024-01-012024-06-300001627281电芯:股权奖励会员2024-01-012024-06-300001627281电芯:Cytovia会员2023-12-310001627281电芯:B类可转换优先股会员2023-11-140001627281电芯:B级认股权证会员2024-01-240001627281电芯:Astra Zeneca会员2024-05-032024-05-030001627281IFRS全面:保留盈余成员2023-12-310001627281电芯:SA免费股票会员2023-06-300001627281电芯:商业诉讼会员2023-12-310001627281电芯:技术设备会员2023-06-300001627281电芯:税务诉讼准备会员2024-06-300001627281建筑物ifrs全文:租赁资产成员2023-12-310001627281电芯:修订协议一会员电芯:Cytovia协议会员ifrs-full:债务证券成员电芯:Cellectis成员2022-04-300001627281电芯:国家担保贷款成员2024-01-012024-06-300001627281电芯:IT许可协议成员2023-12-310001627281电芯:后续投资协议成员电芯:2024年资本演进成员2024-01-012024-06-300001627281最高限度会员电芯:股权奖励成员2024-01-012024-06-300001627281ifrs-full:股份溢价会员2023-01-012023-06-300001627281clls: 电芯B期权成员2024-06-300001627281clls: Cellectis Sa成员2024-01-012024-06-300001627281最低限度会员clls: 股权奖励成员2023-01-012023-06-300001627281ifrs-full:股份溢价会员2024-06-300001627281clls: 波动率成员2023-11-140001627281clls: 电芯B期权成员电芯:欧洲投资银行贷款会员2023-04-172023-04-170001627281电芯:高管雇员会员电芯:股票期权1会员2024-05-152024-05-150001627281电芯:许可和合作协议会员2024-06-300001627281电芯:B档认股权证会员电芯:欧洲投资银行贷款会员2024-01-252024-01-250001627281电芯:高管雇员会员电芯:股票期权1会员2024-06-262024-06-2600016272812024-05-032024-05-030001627281电芯:税务诉讼成员的准备金2024-01-012024-06-300001627281ifrs全文:租赁资产成员2024-06-3000016272812023-04-012023-06-300001627281ifrs-full:在建工程成员2024-01-012024-06-3000016272812024-05-030001627281电芯:临床和研发协议成员ifrs-full:晚于五年的会员2024-06-300001627281电芯:员工诉讼和解职成员2024-01-012024-06-300001627281电芯:B轮认股权成员2024-06-300001627281电芯:执行员工成员clls:股票期权1成员2024-01-252024-01-250001627281clls:人员支出成员2024-01-012024-06-300001627281clls:IT许可协议成员ifrs-full:一年后但不迟于三年成员2024-06-300001627281clls:研发支出成员2024-01-012024-06-300001627281国家: 法国2023-04-012023-06-300001627281clls:后续投资协议成员2024-01-012024-06-300001627281clls:B类可转换优先股成员电芯:后续投资协议成员电芯:2024资本演进成员2024-06-300001627281电芯:股权奖励成员2023-01-012023-06-300001627281电芯:员工成员电芯:SA免费股份成员2021-01-012021-12-310001627281ifrs-full:固定装置成员2024-06-300001627281ifrs-full:固定装置成员2024-01-012024-06-300001627281电芯:货币翻译调整成员2022-12-310001627281电芯:南非免费股份会员2024-06-300001627281电芯:法国国家投资银行会员2024-01-012024-06-300001627281电芯:远期外汇汇率会员2024-05-030001627281ifrs-full:晚于五年的会员电芯:许可和合作协议会员2024-06-300001627281电芯:临床和研发协议会员IFRS-全面收录:三年以上但不超过五年的成员2023-12-310001627281电芯:A档认股权证会员2024-06-300001627281电芯: A档 期权 成员2023-04-170001627281电芯: B档 期权 成员2024-01-252024-01-250001627281电芯: 许可与合作协议 成员IFRS-全面收录:三年以上但不超过五年的成员2023-12-310001627281普通股份成员2023-06-300001627281电芯: Cellectis Sa 成员ifrs-full:股份溢价会员2023-01-012023-06-3000016272812023-06-3000016272812024-04-012024-06-3000016272812023-01-012023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2023-01-012023-06-300001627281电芯: 授予和可退还预付款协议成员2023-03-080001627281电芯: B期权成员2024-01-250001627281电芯: 货币翻译调整成员2023-12-310001627281电芯: Calyxt 公司成员普通股份成员2023-05-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2023-12-310001627281电芯:技术设备成员2022-12-310001627281ifrs完整版:归属于母公司股东的权益成员2023-01-012023-06-300001627281电芯:非雇员权证成员2024-06-300001627281电芯:后续投资协议成员2023-11-010001627281ifrs-full:固定装置成员2023-12-310001627281ifrs-full:晚于五年的会员2024-06-300001627281电芯:Primera Therapeutics Inc成员2024-01-012024-06-300001627281电芯:许可和合作协议成员IFRS-全面收录:三年以上但不超过五年的成员2024-06-300001627281CLLS:货币翻译调整成员2023-06-300001627281ifrs-full:在建工程成员2022-12-310001627281CLLS:期权1成员CLLS:非执行雇员成员2024-06-262024-06-260001627281建筑物ifrs全文:租赁资产成员2022-12-310001627281CLLS:A档认股权证成员2023-04-170001627281电芯:Calyxt成员2023-01-012023-06-300001627281电芯:携带金额和价值成员2023-12-310001627281电芯:Cellectis公司成员2024-01-012024-06-300001627281电芯:期权1成员2024-01-012024-06-300001627281电芯:销售总部和行政费用1成员2023-04-012023-06-300001627281电芯:SA免费股份成员2023-01-012023-06-300001627281电芯:IT许可协议成员ifrs-full:一年后但不迟于三年成员2023-12-310001627281电芯员工诉讼和离职成员2024-06-300001627281ifrs-full:不迟于一年会员2023-12-310001627281电芯非员工认股权证成员2023-01-012023-12-310001627281电芯A类普通股成员电芯Cibus Global Llc成员2023-05-310001627281电芯B档认股权证成员2024-01-012024-06-300001627281电芯研发支出成员2023-04-012023-06-300001627281ifrs全文:土地和建筑成员2022-12-310001627281CLLS:修正协议一名成员CLLS: Cytovia 协议成员ifrs-full:债务证券成员CLLS: Cytovia 成员CLLS: 修订并重新订立协议成员CLLS: Cellectis 成员2023-02-012023-06-300001627281国家: 法国2023-01-012023-06-300001627281ifrs完整版:归属于母公司股东的权益成员2024-01-012024-06-300001627281IFRS全面:其他综合收益累计额成员2024-06-300001627281电芯: 向爱尔兰AZ公司大额可转让研究成本再计费会员2024-06-300001627281电芯: IT 许可协议会员ifrs-full:不迟于一年会员2024-06-300001627281最低限度会员电芯: 联合合作和研究协议会员2023-11-010001627281普通股份成员2023-01-012023-06-300001627281电芯: IT 许可协议会员ifrs-full:晚于五年的会员2023-12-310001627281电芯: 无风险利率成员2023-12-310001627281电芯: 临床和研发协议成员ifrs-full:一年后但不迟于三年成员2023-12-310001627281电芯: 销售总务费用1成员2023-01-012023-06-300001627281电芯: Calyxt Inc成员电芯: A类普通股成员2023-05-310001627281电芯: Cibus成员2024-04-012024-06-300001627281电芯:已租赁场所会员纽约2024-06-300001627281电芯:SA免费股票会员2022-12-310001627281电芯:Cellectis Sa会员ifrs-full:股份溢价会员2024-01-012024-06-300001627281电芯:拨款和可退还预付协议会员2023-10-060001627281电芯:Calyxt会员2023-05-310001627281电芯:阿斯利康会员ifrs-full:股份溢价会员电芯: 资本进化2024会员2024-01-012024-06-300001627281ifrs-full:固定装置成员2022-12-310001627281ifrs-full:超过一年但不超过五年的其他长期负债2024-06-300001627281电芯: 初始投资协议会员2023-11-012023-11-010001627281ifrs完整版:非控制权益成员2023-01-012023-06-300001627281电芯: 其他费用准备会员2023-12-310001627281电芯: 养老金会员2023-12-310001627281clls:阿斯利康爱尔兰成员2024-01-012024-06-300001627281普通股份成员2024-01-012024-06-300001627281clls:货币翻译调整成员2024-06-300001627281clls:联合合作与研究协议成员2024-06-300001627281clls:A类可转换优先股成员clls:后续投资协议成员clls:2024年资本演变成员2024-06-300001627281clls:欧洲投资银行贷款成员2024-01-250001627281电芯: 员工诉讼和解职成员2023-12-310001627281电芯: A档认股权证成员2023-12-310001627281ifrs全文:土地和建筑成员2023-06-300001627281电芯: A档认股权证成员2023-04-172023-12-310001627281电芯: IT许可协议成员ifrs-full:不迟于一年会员2023-12-310001627281电芯: 远期外汇汇率成员2023-12-310001627281电芯: 研发费用成员2024-04-012024-06-300001627281非雇员认购权会员2022-01-012022-12-310001627281卡利特自动取款机项目会员塞勒西斯公司会员2023-05-312023-05-310001627281ifrs全文:租赁资产成员2023-01-012023-06-300001627281国家担保贷款会员最低限度会员2024-06-300001627281阿斯利康公司会员2023-12-310001627281IFRS全面:其他综合收益累计额成员2023-06-300001627281ifrs-full:一年后但不迟于三年成员2024-06-300001627281电芯:国家担保贷款成员2023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2023-06-300001627281IFRS全面:保留盈余成员2024-01-012024-06-300001627281电芯:Cibus成员2024-01-012024-06-300001627281电芯:于二零二一年获准成员电芯:执行官成员clls:SA免费股份会员2021-01-012021-12-310001627281clls:Cytovia协议会员clls:Cellectis会员2021-10-012021-12-310001627281ifrs完整版:非控制权益成员2023-06-300001627281ifrs全文:土地和建筑成员2023-12-310001627281clls:Cytovia协议会员clls:首席会员2024-06-300001627281clls:Cellectis Sa会员ifrs完整版:归属于母公司股东的权益成员2024-01-012024-06-300001627281ifrs完整版:归属于母公司股东的权益成员2023-12-310001627281电芯:A档认股权证会员2023-04-172023-04-170001627281电芯:Cytovia会员2024-06-300001627281电芯:Cytovia协议会员电芯:可转换票据会员电芯:Cytovia会员2024-06-300001627281电芯:销售总务及行政费用1会员2024-04-012024-06-3000016272812023-12-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2022-12-310001627281clls:欧洲投资银行贷款成员2024-01-012024-06-300001627281clls:初始投资协议成员2023-11-010001627281ifrs-full:在建工程成员2023-01-012023-06-300001627281ifrs全文:土地和建筑成员2024-06-300001627281clls:A轮认股权证成员2023-04-170001627281普通股份成员2024-06-300001627281电芯: 执行官成员电芯: SA免费股份成员2024-01-012024-06-300001627281建筑物ifrs全文:租赁资产成员2024-06-300001627281ifrs-full:在建工程成员2023-12-310001627281ifrs-full:股份溢价会员2023-06-300001627281国家:美国2024-01-012024-06-300001627281电芯: 货币翻译调整成员2023-01-012023-06-300001627281IFRS全面:保留盈余成员2023-06-300001627281CLLS:Alpha 2临床试验Servier许可协议成员2024-01-012024-06-300001627281CLLS:技术设备成员2023-01-012023-06-300001627281ifrs-full:一年后但不迟于三年成员CLLS:许可和合作协议成员2024-06-300001627281CLLS:技术设备成员2024-06-3000016272812023-11-142023-11-1400016272812022-12-310001627281CLLS:Tranche B warrants成员CLLS:欧洲投资银行贷款成员2024-01-250001627281临床和研发协议成员IFRS-全面收录:三年以上但不超过五年的成员2024-06-300001627281非雇员认股权证成员2023-06-300001627281临床和研发协议成员ifrs-full:不迟于一年会员2023-12-310001627281ifrs-full:不迟于一年会员许可和合作协议成员2024-06-300001627281国家:美国2024-04-012024-06-300001627281电芯:养老金会员2024-06-300001627281电芯:A级认股权证会员2024-06-300001627281电芯:卡里斯特会员2023-04-242023-04-240001627281ifrs-full:晚于五年的会员电芯:许可和合作协议会员2023-12-310001627281ifrs-full:不迟于一年会员电芯:许可和合作协议会员2023-12-310001627281电芯:非雇员认股权证会员2022-12-310001627281电芯:授予和可退款预付款协议成员ifrs-full:AtFairValueMember2024-01-012024-06-300001627281电芯:IT许可协议成员ifrs-full:晚于五年的会员2024-06-300001627281电芯:估计公允价值成员2023-12-310001627281ifrs全文:租赁资产成员2022-12-310001627281电芯:临床和研发协议成员ifrs-full:晚于五年的会员2023-12-310001627281电芯:Calyxt会员2023-05-312023-05-310001627281电芯:阿斯利康会员电芯:联合合作与研究协议会员2023-11-012023-11-010001627281电芯:受限股票单位会员2023-01-012023-06-300001627281ifrs-full:固定装置成员2023-01-012023-06-300001627281普通股份成员2022-12-310001627281电芯:期权1会员2023-06-300001627281电芯:人事费用会员2023-01-012023-06-300001627281电芯:人员费用会员2023-04-012023-06-300001627281电芯:人员费用会员2024-04-012024-06-300001627281电芯:其他费用准备会员2024-01-012024-06-300001627281电芯:期权 1 会员2022-12-310001627281ifrs-full:OfficeEquipmentMemberifrs全文:租赁资产成员2024-01-012024-06-300001627281电芯:A 揭示权证会员电芯:欧洲投资银行贷款会员2023-04-172023-04-170001627281电芯:养老金会员2024-01-012024-06-300001627281电芯:商业诉讼会员2024-06-300001627281电芯:2024资本演进会员2024-03-050001627281ifrs-full:固定装置成员2023-06-300001627281电芯:Cibus Inc会员2024-06-300001627281电芯:非雇员期权会员2023-12-310001627281电芯:国家担保贷款会员2024-06-300001627281电芯:Cibus Global Llc会员2023-06-012023-06-010001627281ifrs完整版:归属于母公司股东的权益成员2024-06-3000016272812023-01-012023-06-300001627281电芯:技术设备成员2024-01-012024-06-300001627281电芯:期权1成员2024-06-300001627281ifrs全文:土地和建筑成员2023-01-012023-06-300001627281建筑物ifrs全文:租赁资产成员2024-01-012024-06-300001627281普通股份成员2023-12-310001627281电芯:临床和研发协议成员ifrs-full:不迟于一年会员2024-06-300001627281电芯:Primera Therapeutics Inc会员2022-12-292022-12-290001627281电芯:销售总务费用1会员2024-01-012024-06-300001627281国家:美国2023-01-012023-06-3000016272812023-06-012024-06-300001627281电芯:商业诉讼会员2024-01-012024-06-300001627281ifrs全文:租赁资产成员2023-06-300001627281ifrs全文:租赁资产成员2024-01-012024-06-300001627281电芯:2024年资本演进会员2024-01-012024-06-300001627281研发费用成员2023-01-012023-06-30iso4217:eur产品电芯xbrli:纯形iso4217:eurxbrli:股份xbrli:股份电芯:权证电芯:期权iso4217:美元指数xbrli:股份iso4217:美元指数电芯:SegmentUnit

美国

证券交易委员会

华盛顿特区20549

表格 6-K/A

Form 6-k(电影编号241179819)之修正案1

外国私人发行人报告

根据13a-16或15d-16条例

根据《1934年证券交易法》第14a-12条提交。

报告日期:九月十一日, 2024

委员会档案编号: 001-36891

cellectis股份有限公司

(根据其章程中指定的登记人的确切名称)

8, rue de la Croix Jarry

75013法国巴黎

+33 1 81 69 16 00

(总部办公地址)

请勾选是否申报或将以20-F表格或40-F表格为封面申报年度报告:

20-F表单 40-F 表格 ☐

如标记√, 表明申报人按照S-t规则101(b)(1)条规定允许以纸本提交6-K表格: ☐

如标记√, 表明申报人按照S-t规则101(b)(7)条规定允许以纸本提交6-K表格: ☐

说明附录

此由Cellectis S.A.(以下简称「公司」)提交的6-K/A表格修正报告(本「修正」)修正了公司提交的6-k表格报告,其中包含截至2024年6月30日及三个月和六个月结束的未经审核的公司简明综合中期基本报表(以下简称「报告」),该报告于2024年8月6日提交给美国证券交易所,仅提供根据S-t规则405和6-k表格一般说明的C.(6)(a)(ii)段格式化iXBRL(行内可扩展业务报告语言)的基本报表。附件101包含行内可扩展业务报告语言中的资讯。


除上述明文规定外,本修正不以任何形式修正、修改、更新或重述报告中呈现的资讯,也不反映报告提交后发生的任何事件。


cellectis S.A.

 

附件中附有的以下文件,已纳入参考。

 

本6-k表格中包含的信息,包括附件99.1,将被视为已纳入 Cellectis S.A. 的F-3(编号333-265826)和S-8(编号333-204205、333-214884、333-222482、333-227717、333-258514、333-267760 和 333-273777)登记声明的参考,除非被随后提交的文件或报告取代。

 

 

 

 

 


EXHIBIT INDEX

 

Exhibit

 

Title

 

 

 

99.1

 

Cellectis S.A.’s interim report for the six-month period ended June 30, 2024.

 

 

 

101 The following materials from Cellectis S.A.’s Report on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Financial Position, (ii) the Condensed Consolidated Statements of Operations (Unaudited), (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Cash Flow (Unaudited), (v) the Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited), and (vi) the Notes to the Interim Consolidated Financial Statements.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

CELLECTIS S.A.

(Registrant)

 

 

 

September 11, 2024

By:

/s/ André Choulika

 

 

André Choulika

 

 

Chief Executive Officer